Impact of catheter ablation and subsequent recurrence of atrial fibrillation on glucose status in patients undergoing continuous glucose monitoring.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 03 2023
Historique:
received: 08 11 2022
accepted: 07 03 2023
entrez: 16 3 2023
pubmed: 17 3 2023
medline: 21 3 2023
Statut: epublish

Résumé

Although glucose metabolism and atrial fibrillation (AF) have complex interrelationships, the impact of catheter ablation of AF on glucose status has not been well evaluated. Continuous glucose monitoring (CGM) with a FreeStyle Libre Pro (Abbott) was performed for 48 h pre-procedure, during the procedure, and for 72 h post-procedure in 58 non-diabetes mellitus (DM) patients with symptomatic AF and 20 patients with supraventricular or ventricular arrhythmias as a control group. All ablation procedures including pulmonary vein isolation were performed successfully. Glucose levels during procedures consistently increased in the AF and control groups (83.1 ± 16.1 to 110.0 ± 20.5 mg/dL and 83.3 ± 14.7 to 98.6 ± 16.3 mg/dL, respectively, P < 0.001 for both), and Δ glucose levels (max minus min/procedure) were greater in the AF group than control group (P < 0.001). There was a trend toward higher mean glucose levels at 72 h after the procedures compared with those before the procedures in both the AF and control groups (from 103.4 ± 15.6 to 106.1 ± 13.0 mg/dL, P = 0.063 and from 100.2 ± 17.1 to 102.9 ± 16.9 mg/dL, P = 0.052). An acute increase in glucose level at the time of early AF recurrence (N = 9, 15.5%) could be detected by simultaneous CGM and ECG monitoring (89.7 ± 18.0 to 108.3 ± 30.5 mg/dL, P = 0.001). In conclusion, although AF ablation caused a statistically significant increase in the glucose levels during the procedures, it did not result in a pathologically significant change after ablation in non-DM patients. Simultaneous post-procedure CGM and ECG monitoring alerted us to possible acute increases in glucose levels at the onset of AF recurrence.

Identifiants

pubmed: 36922617
doi: 10.1038/s41598-023-31139-0
pii: 10.1038/s41598-023-31139-0
pmc: PMC10017667
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4299

Informations de copyright

© 2023. The Author(s).

Références

Clin Res Cardiol. 2012 Mar;101(3):217-25
pubmed: 22102100
Circ J. 2017 Nov 24;81(12):1749-1757
pubmed: 29070758
J Mol Cell Cardiol. 2010 Nov;49(5):851-63
pubmed: 20655923
J Diabetes Complications. 2018 May;32(5):501-511
pubmed: 29653902
Crit Care Med. 2007 Sep;35(9 Suppl):S508-18
pubmed: 17713401
BMC Cardiovasc Disord. 2021 Feb 15;21(1):90
pubmed: 33588759
J Cardiovasc Electrophysiol. 2011 Nov;22(11):1193-8
pubmed: 21615812
J Cardiovasc Electrophysiol. 2009 Oct;20(10):1186-9
pubmed: 19563367
N Engl J Med. 1998 Sep 3;339(10):659-66
pubmed: 9725923
PLoS Biol. 2018 Jul 24;16(7):e2005143
pubmed: 30040822
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
J Am Coll Cardiol. 2008 Feb 5;51(5):585-94
pubmed: 18237690
Am J Cardiol. 2019 Dec 15;124(12):1881-1888
pubmed: 31668346
Nutr Res. 2020 Aug;80:36-43
pubmed: 32679434
Diabetes Technol Ther. 2015 Nov;17(11):787-94
pubmed: 26171659
Diabet Med. 2012 Apr;29(4):420-33
pubmed: 22288687
Heart Rhythm. 2006 Dec;3(12):1428-35
pubmed: 17161785
Am J Cardiol. 2009 May 1;103(9):1249-54
pubmed: 19406267
PLoS One. 2018 Jun 28;13(6):e0199505
pubmed: 29953508
Best Pract Res Clin Endocrinol Metab. 2001 Dec;15(4):533-51
pubmed: 11800522
Anesth Analg. 2010 Dec;111(6):1378-87
pubmed: 20889933
Circulation. 1999 Nov 30;100(22):2237-43
pubmed: 10577997
Nat Rev Cardiol. 2021 Mar;18(3):210-225
pubmed: 33051613
Lancet. 2009 May 23;373(9677):1798-807
pubmed: 19465235

Auteurs

Masako Baba (M)

Department of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Kentaro Yoshida (K)

Department of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan. kenyoshi@md.tsukuba.ac.jp.
Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan. kenyoshi@md.tsukuba.ac.jp.

Akihiko Nogami (A)

Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Yuichi Hanaki (Y)

Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Yasuaki Tsumagari (Y)

Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Masayuki Hattori (M)

Department of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Hideyuki Hasebe (H)

Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Akito Shikama (A)

Department of Endocrinology and Metabolism, Ibaraki Prefectural Central Hospital, Kasama, Japan.

Hitoshi Iwasaki (H)

Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Noriyuki Takeyasu (N)

Department of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan.

Masaki Ieda (M)

Department of Cardiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH